Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.4.4 (
adenosine deaminase
)
5,136
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Melanoma cells utilize multiple mechanisms to exit the primary tumor mass, invade the surroundings and subsequently distant tissues. We have previously reported that the expression of the RNA editing enzyme ADAR1 (
adenosine deaminase
acting on RNA) is downregulated in metastatic melanoma, which facilitates proliferation and invasion. Here we show that ADAR1 controls melanoma invasiveness by regulating
ITGB3
expression via miR-30a and miR-30d. ADAR1 overexpression or knockdown leads to an increase or decrease, respectively, in the expression of both microRNAs. The effect is independent of RNA-editing. Dual luciferase assays show that both microRNAs directly regulate the expression of the
ITGB3
integrin. Overexpression of the miR-30a or miR-30d lead to a decrease in
ITGB3
and a resultant decreased invasive and metastatic capacities. Neutralization of the endogenous miR-30a or miR-30d leads to the opposite effect. The microRNAs regulate
ITGB3
levels probably through a post-transcriptional effect, as both mRNA and protein levels of
ITGB3
are affected. These results further expand our knowledge on the ADAR1-
ITGB3
network and its central role in acquisition of the invasive phenotype of metastatic melanoma.
...
PMID:ADAR1 regulates melanoma cell invasiveness by controlling beta3-integrin via microRNA-30 family members. 3290 49